For 17 years, Ken Jones fought fires in San Francisco. Now, he is fighting cancer -- and the insurance company that insures ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC).

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...

With most lung cancers in India diagnosed at advanced stages, experts say low-dose CT screening for high-risk groups like ...

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Projected losses in Medicaid coverage as a result of President Trump's "One Big Beautiful Bill" could result in more than 1 million missed cancer screenings and hundreds of avoidable deaths within 2 ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

In the same week that Servier announced its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has ...

Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...